Concepts (261)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 23 | 2018 | 438 | 5.160 |
Why?
|
| Population Surveillance | 11 | 2021 | 263 | 3.710 |
Why?
|
| Hepatitis C | 5 | 2020 | 65 | 2.690 |
Why?
|
| Disabled Persons | 5 | 2023 | 35 | 2.650 |
Why?
|
| Registries | 20 | 2021 | 471 | 2.450 |
Why?
|
| United States | 46 | 2022 | 3956 | 2.060 |
Why?
|
| Humans | 65 | 2023 | 17611 | 1.460 |
Why?
|
| Incidence | 23 | 2021 | 1255 | 1.360 |
Why?
|
| Survivors | 6 | 2016 | 149 | 1.250 |
Why?
|
| Adult | 36 | 2022 | 7598 | 1.240 |
Why?
|
| Mammography | 8 | 2015 | 169 | 1.200 |
Why?
|
| Breast Neoplasms | 14 | 2018 | 949 | 1.160 |
Why?
|
| Young Adult | 17 | 2021 | 2427 | 1.080 |
Why?
|
| Female | 47 | 2021 | 12608 | 1.050 |
Why?
|
| Anthracyclines | 2 | 2016 | 14 | 1.030 |
Why?
|
| Developmental Disabilities | 4 | 2023 | 52 | 1.030 |
Why?
|
| Adolescent | 18 | 2023 | 3651 | 1.020 |
Why?
|
| Aged | 28 | 2022 | 6095 | 1.020 |
Why?
|
| Early Detection of Cancer | 6 | 2015 | 501 | 1.000 |
Why?
|
| Middle Aged | 33 | 2021 | 7911 | 0.980 |
Why?
|
| Male | 34 | 2021 | 10008 | 0.920 |
Why?
|
| Liver Neoplasms | 2 | 2021 | 40 | 0.870 |
Why?
|
| Poliovirus | 1 | 2022 | 1 | 0.850 |
Why?
|
| Poliovirus Vaccine, Oral | 1 | 2022 | 3 | 0.850 |
Why?
|
| Poliomyelitis | 1 | 2022 | 2 | 0.850 |
Why?
|
| Mass Screening | 8 | 2020 | 661 | 0.820 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 201 | 0.820 |
Why?
|
| Hepatitis C, Chronic | 2 | 2020 | 64 | 0.780 |
Why?
|
| Gallbladder Neoplasms | 1 | 2021 | 3 | 0.780 |
Why?
|
| Bile Duct Neoplasms | 1 | 2021 | 5 | 0.770 |
Why?
|
| Vaccination | 2 | 2023 | 635 | 0.710 |
Why?
|
| Disease Notification | 1 | 2020 | 7 | 0.710 |
Why?
|
| Child | 13 | 2023 | 2474 | 0.690 |
Why?
|
| Hepacivirus | 1 | 2019 | 51 | 0.660 |
Why?
|
| SEER Program | 10 | 2017 | 91 | 0.630 |
Why?
|
| Sex Distribution | 7 | 2017 | 190 | 0.600 |
Why?
|
| Public Health Administration | 1 | 2017 | 6 | 0.580 |
Why?
|
| Age Distribution | 9 | 2017 | 246 | 0.570 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2016 | 7 | 0.550 |
Why?
|
| Cardiotoxins | 1 | 2014 | 1 | 0.490 |
Why?
|
| Echocardiography, Stress | 1 | 2014 | 2 | 0.490 |
Why?
|
| Heart Rate | 1 | 2014 | 40 | 0.480 |
Why?
|
| Prevalence | 5 | 2019 | 884 | 0.480 |
Why?
|
| Breast | 1 | 2015 | 84 | 0.470 |
Why?
|
| Heart Diseases | 1 | 2014 | 77 | 0.460 |
Why?
|
| Exercise | 2 | 2018 | 489 | 0.450 |
Why?
|
| Child, Preschool | 8 | 2023 | 1409 | 0.440 |
Why?
|
| Aged, 80 and over | 11 | 2021 | 1900 | 0.420 |
Why?
|
| Quality of Life | 1 | 2016 | 507 | 0.420 |
Why?
|
| Medicare | 4 | 2022 | 202 | 0.400 |
Why?
|
| Ovarian Neoplasms | 2 | 2014 | 49 | 0.390 |
Why?
|
| Infant, Newborn | 5 | 2021 | 844 | 0.380 |
Why?
|
| Neoplasm Invasiveness | 5 | 2017 | 78 | 0.360 |
Why?
|
| Poverty | 4 | 2015 | 166 | 0.350 |
Why?
|
| Infant | 5 | 2021 | 1171 | 0.350 |
Why?
|
| Survival Rate | 5 | 2017 | 260 | 0.350 |
Why?
|
| Autism Spectrum Disorder | 2 | 2023 | 163 | 0.340 |
Why?
|
| Age Factors | 6 | 2015 | 917 | 0.330 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2008 | 6 | 0.320 |
Why?
|
| Mouth Neoplasms | 1 | 2008 | 9 | 0.320 |
Why?
|
| Nutrition Surveys | 2 | 2018 | 61 | 0.320 |
Why?
|
| Disability Evaluation | 2 | 2006 | 46 | 0.280 |
Why?
|
| Papillomavirus Infections | 1 | 2008 | 133 | 0.280 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2017 | 16 | 0.280 |
Why?
|
| Time Factors | 7 | 2018 | 1086 | 0.270 |
Why?
|
| Health Services Accessibility | 4 | 2020 | 289 | 0.260 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 318 | 0.230 |
Why?
|
| Risk Factors | 3 | 2021 | 3325 | 0.220 |
Why?
|
| Immunization | 1 | 2023 | 68 | 0.210 |
Why?
|
| New York | 1 | 2022 | 20 | 0.210 |
Why?
|
| Vaccination Coverage | 1 | 2023 | 41 | 0.210 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2022 | 382 | 0.210 |
Why?
|
| Activities of Daily Living | 1 | 2003 | 85 | 0.210 |
Why?
|
| Colorectal Neoplasms | 5 | 2018 | 613 | 0.210 |
Why?
|
| Neoplasm Staging | 4 | 2017 | 325 | 0.200 |
Why?
|
| Health Care Surveys | 2 | 2021 | 230 | 0.200 |
Why?
|
| Intention | 1 | 2021 | 28 | 0.190 |
Why?
|
| Phthiraptera | 1 | 2021 | 1 | 0.190 |
Why?
|
| Mycoplasma | 1 | 2021 | 1 | 0.190 |
Why?
|
| Dysentery, Bacillary | 1 | 2021 | 2 | 0.190 |
Why?
|
| Zika Virus | 1 | 2021 | 2 | 0.190 |
Why?
|
| Zika Virus Infection | 1 | 2021 | 4 | 0.190 |
Why?
|
| Gonorrhea | 1 | 2021 | 18 | 0.190 |
Why?
|
| Chlamydia Infections | 1 | 2021 | 25 | 0.190 |
Why?
|
| Syphilis | 1 | 2021 | 17 | 0.190 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2021 | 54 | 0.180 |
Why?
|
| Parents | 1 | 2023 | 296 | 0.180 |
Why?
|
| Death Certificates | 2 | 2017 | 19 | 0.170 |
Why?
|
| American Cancer Society | 2 | 2017 | 12 | 0.170 |
Why?
|
| Acute Disease | 1 | 2020 | 142 | 0.170 |
Why?
|
| Sex Factors | 3 | 2017 | 643 | 0.170 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 1322 | 0.170 |
Why?
|
| Comorbidity | 1 | 2021 | 594 | 0.160 |
Why?
|
| Data Collection | 2 | 2017 | 256 | 0.160 |
Why?
|
| Residence Characteristics | 3 | 2015 | 248 | 0.160 |
Why?
|
| Health Status Disparities | 2 | 2017 | 146 | 0.150 |
Why?
|
| Cultural Diversity | 1 | 2018 | 17 | 0.150 |
Why?
|
| Tobacco Use | 1 | 2018 | 15 | 0.150 |
Why?
|
| Diabetes Mellitus | 1 | 2003 | 487 | 0.150 |
Why?
|
| Financing, Government | 2 | 2008 | 28 | 0.150 |
Why?
|
| Cause of Death | 2 | 2016 | 181 | 0.150 |
Why?
|
| Influenza Vaccines | 1 | 2020 | 267 | 0.150 |
Why?
|
| Influenza, Human | 1 | 2020 | 263 | 0.150 |
Why?
|
| Models, Statistical | 1 | 2018 | 177 | 0.150 |
Why?
|
| Vital Statistics | 1 | 2017 | 1 | 0.140 |
Why?
|
| Patient Selection | 2 | 2015 | 190 | 0.140 |
Why?
|
| Cancer Survivors | 1 | 2018 | 83 | 0.140 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2017 | 33 | 0.140 |
Why?
|
| Hospitalization | 1 | 2022 | 797 | 0.140 |
Why?
|
| Cardiotoxicity | 1 | 2016 | 1 | 0.140 |
Why?
|
| Women's Health Services | 2 | 2006 | 20 | 0.140 |
Why?
|
| Health Policy | 1 | 2017 | 122 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 129 | 0.130 |
Why?
|
| Diet | 2 | 2018 | 365 | 0.130 |
Why?
|
| Linear Models | 1 | 2016 | 231 | 0.130 |
Why?
|
| Preventive Health Services | 2 | 2008 | 159 | 0.130 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 28 | 0.130 |
Why?
|
| Patient Care Planning | 1 | 2015 | 52 | 0.130 |
Why?
|
| Information Dissemination | 1 | 2015 | 51 | 0.130 |
Why?
|
| Symptom Assessment | 1 | 2015 | 6 | 0.130 |
Why?
|
| Public Health | 1 | 2015 | 80 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2015 | 86 | 0.120 |
Why?
|
| HIV Infections | 1 | 2021 | 694 | 0.120 |
Why?
|
| Uterine Neoplasms | 1 | 2014 | 12 | 0.120 |
Why?
|
| Indians, North American | 1 | 2014 | 49 | 0.110 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 142 | 0.110 |
Why?
|
| Logistic Models | 3 | 2013 | 926 | 0.110 |
Why?
|
| Medicine | 2 | 2009 | 22 | 0.110 |
Why?
|
| Socioeconomic Factors | 4 | 2022 | 630 | 0.100 |
Why?
|
| Medical Oncology | 2 | 2009 | 32 | 0.100 |
Why?
|
| Endocrine System Diseases | 1 | 2011 | 2 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 103 | 0.100 |
Why?
|
| Patient Satisfaction | 1 | 2013 | 211 | 0.100 |
Why?
|
| Stress, Psychological | 1 | 2013 | 141 | 0.100 |
Why?
|
| Obesity | 1 | 2018 | 837 | 0.100 |
Why?
|
| Counseling | 1 | 2013 | 189 | 0.100 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 709 | 0.090 |
Why?
|
| Electronic Health Records | 1 | 2015 | 681 | 0.090 |
Why?
|
| Pandemics | 2 | 2023 | 287 | 0.090 |
Why?
|
| Carcinoma, Lobular | 1 | 2009 | 10 | 0.080 |
Why?
|
| Carcinoma in Situ | 1 | 2009 | 17 | 0.080 |
Why?
|
| Databases as Topic | 1 | 2008 | 19 | 0.080 |
Why?
|
| Tongue Neoplasms | 1 | 2008 | 1 | 0.080 |
Why?
|
| Tonsillar Neoplasms | 1 | 2008 | 2 | 0.080 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2009 | 53 | 0.080 |
Why?
|
| Continuity of Patient Care | 1 | 2009 | 105 | 0.080 |
Why?
|
| Animals | 6 | 2021 | 259 | 0.080 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2008 | 12 | 0.080 |
Why?
|
| Women's Health | 2 | 2006 | 200 | 0.080 |
Why?
|
| Gastrointestinal Diseases | 1 | 2007 | 27 | 0.070 |
Why?
|
| Program Development | 1 | 2006 | 69 | 0.070 |
Why?
|
| Primary Prevention | 1 | 2006 | 73 | 0.060 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2006 | 119 | 0.060 |
Why?
|
| Polychlorinated Biphenyls | 1 | 1984 | 11 | 0.060 |
Why?
|
| Emergencies | 1 | 2023 | 6 | 0.060 |
Why?
|
| Adipose Tissue | 1 | 1984 | 58 | 0.060 |
Why?
|
| Hydrocodone | 1 | 1982 | 1 | 0.050 |
Why?
|
| Codeine | 1 | 1982 | 2 | 0.050 |
Why?
|
| Analgesics | 1 | 1982 | 27 | 0.050 |
Why?
|
| Narcotic Antagonists | 1 | 1982 | 16 | 0.050 |
Why?
|
| Education, Special | 1 | 2022 | 3 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2003 | 297 | 0.050 |
Why?
|
| Genitalia | 1 | 2021 | 1 | 0.050 |
Why?
|
| Length of Stay | 1 | 2022 | 181 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 568 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2023 | 1115 | 0.050 |
Why?
|
| Seasons | 1 | 2020 | 102 | 0.050 |
Why?
|
| Patient Readmission | 1 | 2022 | 163 | 0.040 |
Why?
|
| Insurance Coverage | 2 | 2012 | 106 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 415 | 0.040 |
Why?
|
| Age of Onset | 1 | 2018 | 79 | 0.040 |
Why?
|
| Tobacco Products | 1 | 2018 | 17 | 0.040 |
Why?
|
| Los Angeles | 1 | 2018 | 139 | 0.040 |
Why?
|
| Minority Groups | 1 | 2018 | 101 | 0.040 |
Why?
|
| Polymers | 4 | 1981 | 5 | 0.040 |
Why?
|
| Appalachian Region | 1 | 2016 | 1 | 0.030 |
Why?
|
| Life Style | 1 | 2018 | 332 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2016 | 24 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 2 | 2008 | 169 | 0.030 |
Why?
|
| Food Coloring Agents | 3 | 1981 | 4 | 0.030 |
Why?
|
| Medicaid | 1 | 2017 | 186 | 0.030 |
Why?
|
| Data Accuracy | 1 | 2016 | 27 | 0.030 |
Why?
|
| Puerto Rico | 1 | 2015 | 5 | 0.030 |
Why?
|
| Breast Neoplasms, Male | 1 | 2015 | 9 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2015 | 50 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2015 | 46 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2016 | 218 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2015 | 51 | 0.030 |
Why?
|
| Biopsy | 1 | 2015 | 74 | 0.030 |
Why?
|
| Alaska | 1 | 2014 | 16 | 0.030 |
Why?
|
| Nebraska | 1 | 2014 | 1 | 0.030 |
Why?
|
| Public Health Surveillance | 1 | 2014 | 42 | 0.030 |
Why?
|
| Dogs | 2 | 1984 | 17 | 0.030 |
Why?
|
| Prognosis | 1 | 2015 | 606 | 0.030 |
Why?
|
| Intestinal Absorption | 4 | 1981 | 5 | 0.030 |
Why?
|
| Kidney | 2 | 1984 | 52 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 381 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2013 | 93 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2012 | 66 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2012 | 237 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2011 | 2447 | 0.030 |
Why?
|
| Marital Status | 1 | 2012 | 21 | 0.030 |
Why?
|
| Georgia | 1 | 2012 | 26 | 0.030 |
Why?
|
| Physical Examination | 1 | 2011 | 20 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2012 | 44 | 0.020 |
Why?
|
| Liver | 2 | 1982 | 32 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 70 | 0.020 |
Why?
|
| Rural Population | 1 | 2012 | 51 | 0.020 |
Why?
|
| Urban Population | 1 | 2012 | 116 | 0.020 |
Why?
|
| Antioxidants | 3 | 1980 | 40 | 0.020 |
Why?
|
| Colonoscopy | 1 | 2013 | 251 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2012 | 671 | 0.020 |
Why?
|
| Professional Practice | 1 | 2009 | 16 | 0.020 |
Why?
|
| Physicians, Family | 1 | 2009 | 44 | 0.020 |
Why?
|
| Rats | 4 | 1982 | 29 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2012 | 244 | 0.020 |
Why?
|
| Specialization | 1 | 2008 | 24 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 1210 | 0.020 |
Why?
|
| Medically Underserved Area | 1 | 2008 | 12 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2012 | 1309 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2012 | 1097 | 0.020 |
Why?
|
| Bile | 3 | 1982 | 4 | 0.020 |
Why?
|
| Community Health Services | 1 | 2008 | 83 | 0.020 |
Why?
|
| Health Surveys | 1 | 2008 | 260 | 0.020 |
Why?
|
| Genital Neoplasms, Female | 1 | 2006 | 2 | 0.020 |
Why?
|
| Anxiety | 1 | 2008 | 150 | 0.020 |
Why?
|
| Papanicolaou Test | 1 | 2006 | 37 | 0.020 |
Why?
|
| Self Care | 1 | 2008 | 163 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2008 | 164 | 0.020 |
Why?
|
| Vaginal Smears | 1 | 2006 | 48 | 0.020 |
Why?
|
| Risk | 1 | 2008 | 516 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2008 | 187 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2008 | 298 | 0.020 |
Why?
|
| Health Promotion | 1 | 2008 | 280 | 0.020 |
Why?
|
| Health Maintenance Organizations | 1 | 2006 | 417 | 0.020 |
Why?
|
| Carbon Radioisotopes | 1 | 1984 | 2 | 0.010 |
Why?
|
| Testis | 1 | 1984 | 2 | 0.010 |
Why?
|
| Omentum | 1 | 1984 | 2 | 0.010 |
Why?
|
| Macaca fascicularis | 1 | 1984 | 3 | 0.010 |
Why?
|
| Myocardium | 1 | 1984 | 6 | 0.010 |
Why?
|
| Adrenal Glands | 1 | 1982 | 1 | 0.010 |
Why?
|
| Spleen | 1 | 1982 | 4 | 0.010 |
Why?
|
| Species Specificity | 1 | 1982 | 6 | 0.010 |
Why?
|
| Food Additives | 2 | 1979 | 3 | 0.010 |
Why?
|
| Lung | 1 | 1982 | 62 | 0.010 |
Why?
|
| Butylated Hydroxytoluene | 1 | 1980 | 1 | 0.010 |
Why?
|
| Oxidoreductases | 1 | 1980 | 1 | 0.010 |
Why?
|
| Intestines | 1 | 1980 | 4 | 0.010 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 1980 | 8 | 0.010 |
Why?
|
| Feces | 4 | 1981 | 80 | 0.010 |
Why?
|
| Azo Compounds | 1 | 1977 | 1 | 0.010 |
Why?
|
| Naphthalenesulfonates | 1 | 1977 | 1 | 0.010 |
Why?
|
| Tartrazine | 1 | 1977 | 1 | 0.010 |
Why?
|
| Organ Size | 1 | 1980 | 15 | 0.000 |
Why?
|
| Vinyl Compounds | 1 | 1978 | 1 | 0.000 |
Why?
|
| Mice, Inbred ICR | 1 | 1978 | 3 | 0.000 |
Why?
|
| Tissue Distribution | 1 | 1978 | 6 | 0.000 |
Why?
|
| Mice | 1 | 1978 | 68 | 0.000 |
Why?
|
| Chromatography, Thin Layer | 1 | 1977 | 1 | 0.000 |
Why?
|
| Colorimetry | 1 | 1977 | 1 | 0.000 |
Why?
|
| Biotransformation | 1 | 1977 | 3 | 0.000 |
Why?
|
Concepts
(261)
Derived automatically from this person's publications.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->